Press Releases



Date Title
11/29/18
Summary ToggleHistogenics and FDA Continue to Discuss NeoCart® Phase 3 Clinical Trial Data and Potential Regulatory Pathway WALTHAM, Mass. , Nov. 29, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation ( Histogenics ) (Nasdaq: HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, today provided an update on the NeoCart regulatory pathway based on its
11/08/18
Summary ToggleHistogenics Corporation Announces Third Quarter 2018 Financial and Operating Results WALTHAM, Mass. , Nov. 08, 2018 (GLOBE NEWSWIRE) -- ‒ Histogenics and FDA Continue Discussions on NeoCart ® Phase 3 Data and Potential BLA Submission ‒ ‒ October 2018 Financing Expected to Provide Funding Into Middle of 2019 ‒ ‒ Histogenics to Host Conference Call and Webcast Today at 8:30 a.m.
11/01/18
Summary ToggleHistogenics and FDA to Continue Discussions on NeoCart Phase 3 Clinical Trial Data and Potential Regulatory Pathway WALTHAM, Mass. , Nov. 01, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation ( Histogenics ) (Nasdaq: HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, today provided an update on the NeoCart regulatory pathway based on
10/25/18
Summary ToggleHistogenics Corporation to Report Third Quarter 2018 Financial Results on November 8, 2018 WALTHAM, Mass. , Oct. 25, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq: HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, announced it will report its third quarter 2018 financial results on November 8, 2018 ,
10/05/18
Summary ToggleHistogenics Corporation Announces Pricing of Public Offering of Common Stock and Warrants WALTHAM, Mass. , Oct. 05, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation ( Histogenics ) (Nasdaq: HSGX), a leader in the development of restorative cell therapies, today announced the pricing of an underwritten public offering of 26,155,000 shares of its common stock and warrants to purchase up
10/04/18
Summary ToggleHistogenics Corporation Announces Proposed Public Offering of Common Stock and Warrants WALTHAM, Mass. , Oct. 04, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation ( Histogenics ) (Nasdaq: HSGX), a leader in the development of restorative cell therapies, today announced that it intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of common
09/26/18
Summary ToggleHistogenics to Meet With FDA to Discuss NeoCart Phase 3 Clinical Trial Data and Potential Regulatory Pathway WALTHAM, Mass. , Sept. 26, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation ( Histogenics ) (Nasdaq: HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, today announced that the U.S.
09/05/18
Summary ToggleHistogenics Announces Top-Line Results From Phase 3 Clinical Trial of NeoCart® in Patients With Knee Cartilage Damage              ‒ Phase 3 Clinical Trial of NeoCart Did Not Meet Primary Endpoint of a Statistically Significant Improvement in Pain and Function in a Dual Threshold Responder Analysis One Year After Treatment as Compared to Microfracture ‒              ‒ NeoCart Demonstrated Statistically Significant
08/09/18
Summary ToggleHistogenics Corporation Announces Second Quarter 2018 Financial and Operating Results ‒ Top-line Superiority Data from NeoCart ® Phase 3 Clinical Trial on Track for Third Quarter of 2018 ‒ ‒ Initiation of Phase 3 Clinical Trial in Japan Expected in Second Half of 2018 ‒ ‒ Expansion of Management Team in Preparation for Potential Commercialization of NeoCart in 2020 ‒ ‒ Company to
07/31/18
Summary ToggleHistogenics Corporation Appoints E. Lynne Kelley, M.D., FACS As Chief Medical Officer Experienced Surgeon and Life Sciences Executive to Lead Medical Affairs, Clinical and Regulatory Operations in Preparation for Potential Commercial Launch of NeoCart® WALTHAM, Mass. , July 31, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation ( Histogenics ) (Nasdaq:HSGX), a leader in the
07/26/18
Summary ToggleHistogenics Corporation to Report Second Quarter 2018 Financial Results on August 9, 2018 WALTHAM, Mass. , July 26, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq:HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, announced it will report its second quarter 2018 financial results on August 9, 2018 ,
07/25/18
Summary ToggleHistogenics Corporation to Present at Canaccord Genuity’s 38th Annual Growth Conference WALTHAM, Mass. , July 25, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation ( Histogenics ) (Nasdaq:HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, announced that Adam Gridley , Chief Executive Officer of Histogenics ,
07/23/18
Summary ToggleHistogenics Chief Operating Officer, Stephen Kennedy Appointed to Advanced Regenerative Manufacturing Institute’s Technology Advisory Sub-Committee WALTHAM, Mass. , July 23, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation ( Histogenics ) (Nasdaq:HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, announced that Stephen Kennedy, Executive Vice President & Chief
05/31/18
Summary ToggleHistogenics Corporation to Host Investor Day on June 19, 2018

WALTHAM, Mass. , May 31, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq:HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, announced that Histogenics will host its first Investor Day on Tuesday, June 19, 2018 , in

05/10/18
Summary ToggleHistogenics Corporation Announces First Quarter 2018 Financial and Operating Results

‒ Top-line Superiority Data from NeoCart ® Phase 3 Clinical Trial and Potential Biologics License Application Submission on Track for Third Quarter of 2018 ‒ ‒ Initiation of Phase 3 Clinical Trial in Japan Expected in Second Half of 2018 ‒ ‒ Company to Host Conference Call and Webcast Today at 8:30

04/26/18
Summary ToggleHistogenics Corporation to Report First Quarter 2018 Financial Results on May 10, 2018

WALTHAM, Mass. , April 26, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq:HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, announced it will report its first quarter 2018 financial results on May 10, 2018 ,

04/18/18
Summary ToggleHistogenics Corporation Announces the Appointment of Susan Washer to Its Board of Directors Experienced Life Sciences Executive to Serve as Member of Histogenics Board of Directors WALTHAM, Mass. , April 18, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation ( Histogenics ) (Nasdaq:HSGX), a leader in the development of restorative cell therapies (RCTs) that may offer rapid-onset pain relief
03/28/18
Summary ToggleHistogenics Corporation to Present at Upcoming Investor Conferences WALTHAM, Mass. , March 28, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation ( Histogenics ) (Nasdaq:HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, announced that Company Management will be presenting at two upcoming
03/19/18
Summary ToggleHistogenics Corporation to Present at Needham & Company’s 17th Annual Healthcare Conference WALTHAM, Mass. , March 19, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation ( Histogenics ) (Nasdaq:HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, announced that Adam Gridley , Chief Executive Officer of Histogenics ,
03/15/18
Summary ToggleHistogenics Corporation Announces Financial and Operating Results for the Fourth Quarter and Year Ended December 31, 2017 NeoCart ® Top-line Phase 3 Clinical Trial Data and Potential Biologics License Application Filing Remain on Track for Third Quarter of 2018 NeoCart Licensing Agreement with MEDINET Co. Ltd. Provides Important Source of Funding and Enables Development and Potential Commercialization in Japanese
03/02/18
Summary ToggleHistogenics to Showcase NeoCart® at American Academy of Orthopedic Surgeons and Orthopedic Research Society 2018 Annual Meetings WALTHAM, Mass. , March 02, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation ( Histogenics ) (Nasdaq:HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, announced today that it will be exhibiting at the American Academy of
03/01/18
Summary ToggleHistogenics Corporation to Report 2017 Financial Results on March 15, 2018 WALTHAM, Mass. , March 01, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq:HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, announced it will report financial results for the quarter and year ended December 31,
02/20/18
Summary ToggleHistogenics Corporation to Present at Upcoming Investor Conferences WALTHAM, Mass. , Feb. 20, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation ( Histogenics ) (Nasdaq:HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, announced that Company Management will be presenting at two upcoming
01/25/18
Summary ToggleHistogenics Corporation Announces Closing of Underwritten Registered Direct Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares WALTHAM, Mass. , Jan. 25, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation ( Histogenics ) (Nasdaq:HSGX), a leader in the development of restorative cell therapies, today announced the closing of its previously announced underwritten registered direct offering of 2,691,494 shares of its common
01/22/18
Summary ToggleHistogenics Corporation Announces Pricing of Underwritten Registered Direct Offering of 2,340,430 Shares of Common Stock WALTHAM, Mass. , Jan. 22, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation ( Histogenics ) (Nasdaq:HSGX), a leader in the development of restorative cell therapies, today announced the pricing of an underwritten registered direct offering of 2,340,430 shares of its common stock at a price of $2.35
01/09/18
Summary ToggleHistogenics Corporation Announces Receipt of $10 Million Up-front Payment for Japanese Neocart Agreement WALTHAM, Mass. , Jan. 09, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation ( Histogenics ) (Nasdaq:HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, announced that it has received the $10 million up-front payment from
12/21/17
Summary ToggleHistogenics Corporation and MEDINET Co., Ltd Enter Into Licensing Agreement for Development and Commercialization of NeoCart for the Japanese Market – Transaction Terms Include a $10 Million Up-front Payment with a Potential of $87 Million in Total Milestones, and Tiered Royalties on Sales ‒ ‒ Japanese Cartilage Repair Market is Large and Growing with Established Reimbursement, and Physicians and Patients Seeking Improved Treatments for
11/09/17
Summary ToggleHistogenics Corporation Announces Third Quarter 2017 Financial and Operating Results  Top-line, 1-year Superiority Data for NeoCart ® Phase 3 Clinical Trial and Potential Biologics License Application Filing Remain on Track for Third Quarter of 2018   Company to Host Conference Call and Webcast Thursday, November 9, 2017 at 8:30 a.m. ET  WALTHAM, Mass. , Nov.
10/26/17
Summary ToggleHistogenics Corporation to Report Third Quarter 2017 Financial Results on November 9, 2017 WALTHAM, Mass. , Oct. 26, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq:HSGX), a leading cell therapy company focused on developing and commercializing products in the musculoskeletal space, announced it will report its third quarter 2017 financial results on Thursday, November 9, 2017
10/12/17
Summary ToggleHistogenics Corporation Promotes Stephen Kennedy to Executive Vice President & Chief Operating Officer WALTHAM, Mass. , Oct. 12, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation ( Histogenics ) (Nasdaq:HSGX), a leading cell therapy company focused on developing and commercializing products in the musculoskeletal space, today announced the promotion of Stephen Kennedy from Chief Technology Officer to
10/02/17
Summary ToggleHistogenics Announces Publication of Additional Biomechanical Data From Human Engineered Cartilage Testing – Data Demonstrate the Importance of Generating Extracellular Matrix During Ex-Vivo Manufacturing of Cartilage Cell Therapy – – Ex-vivo Production of Extracellular Matrix is Critical to Biomechanical Competence and May Enable Earlier Return to Function After Treatment – – Presence of Extracellular
09/26/17
Summary ToggleHistogenics Corporation to Present at the 2017 Cell & Gene Meeting on the Mesa WALTHAM, Mass. , Sept. 26, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation ( Histogenics ) (Nasdaq:HSGX), a leading cell therapy company focused on developing and commercializing products in the musculoskeletal space, today announced that Adam Gridley , President and Chief Executive Officer of
08/24/17
Summary ToggleHistogenics Corporation to Present at Upcoming Investor Conferences WALTHAM, Mass. , Aug. 24, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation ( Histogenics ) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Company Management will be presenting at three upcoming
08/10/17
Summary ToggleHistogenics Corporation Announces Second Quarter 2017 Financial and Operating Results ‒ Completed Enrollment in NeoCart ® Phase 3 Clinical Trial ‒ ‒ Top-line Data and Potential BLA Filing Expected in Third Quarter of 2018 ‒ ‒ Defined Regulatory Pathway with Japan Pharmaceuticals and Medical Devices Agency ‒ ‒ Market Research in U.S.
07/27/17
Summary ToggleHistogenics Corporation to Announce Second Quarter 2017 Financial Results on August 10, 2017 WALTHAM, Mass. , July 27, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, announced it will release its financial and operational results for the quarter ended June 30,
07/26/17
Summary ToggleHistogenics Corporation to Present at the 37th Annual Canaccord Genuity Growth Conference WALTHAM, Mass. , July 26, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation ( Histogenics ) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Adam Gridley , President and Chief Executive Officer of
07/11/17
Summary ToggleHistogenics Announces Publication of Data From Collagen and Chondrocyte 3-D Bioprinting Study – Findings Augment Growing Body of Information to Support the Manufacture of Current and Next-Generation NeoCart ® Implants –  – 3-D Bioprinting May Enable More Efficient Production of Next Generation NeoCart Implants – WALTHAM, Mass. , July 11, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation (
06/27/17
Summary ToggleHistogenics Completes Enrollment for Phase 3 Clinical Trial of Neocart® to Treat Knee Cartilage Damage – On Track for Top-Line One Year Superiority Data and Potential BLA  Filing in Third Quarter of 2018 – Articular cartilage can be damaged by injury or normal wear and tear (http://www.neocartimplant.com/cartilage-injury). – Novel Tissue Implant Potentially Accelerates Recovery and Reduces Pain
06/05/17
Summary ToggleHistogenics Corporation Announces the Appointment of Donald Haut, Ph.D. as Chief Business Officer ‒ Experienced Biotechnology Business Development & Strategic Planning Executive to Lead Commercial Partnership Activities ‒ WALTHAM, Mass. , June 05, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation ( Histogenics ) (Nasdaq:HSGX), a regenerative medicine company focused on developing and
05/16/17
Summary ToggleHistogenics Corporation to Present at Upcoming Industry Conferences WALTHAM, Mass. , May 16, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation ( Histogenics ) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Management will be presenting at several upcoming industry
05/15/17
Summary ToggleHistogenics Corporation Receives Innovation Award ‒ Histogenics Recognized by the Smaller Business Association of New England (SBANE) as One of the Most Innovative Companies in the Region ‒ ‒ NeoCart ® and Tissue Generation Platform Seen as a Potential Leading Solution to Treat Cartilage Defects ‒ WALTHAM, Mass.
05/11/17
Summary ToggleHistogenics Corporation Announces First Quarter 2017 Financial and Operating Results ‒ NeoCart ® Phase 3 Clinical Trial Enrollment Near Completion ‒ ‒ NeoCart Approval Pathway in Japan Defined After Successful Conclusion of Discussions with the Japan Pharmaceuticals and Medical Devices Agency ‒ ‒ Publication of Additional Data to Support Potential Approval and Commercialization of
05/08/17
Summary ToggleHistogenics Announces Agreement With the Japan Pharmaceuticals and Medical Devices Agency Regarding Japanese Regulatory Pathway for NeoCart® – Long history and significant US data package may enable full Marketing and Manufacturing Authorization of NeoCart subject to successful completion of small confirmatory clinical trial in Japan – – PMDA Consultations concluded in first quarter of 2017 encompass all parts of potential regulatory
04/27/17
Summary ToggleHistogenics Corporation To Announce First Quarter 2017 Financial Results on May 11, 2017 WALTHAM, Mass. , April 27, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, announced it will release its financial and operational results for the quarter ended March 31,
04/24/17
Summary ToggleHistogenics Corporation to Present at 5th Annual Cell & Gene Therapy Investor Day on April 27, 2017 WALTHAM, Mass. , April 24, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation ( Histogenics ) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Adam Gridley , President & CEO, will present at the
03/29/17
Summary ToggleHistogenics Corporation to Present at Needham & Company’s 16th Annual Healthcare Conference WALTHAM, Mass. , March 29, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation ( Histogenics ) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Adam Gridley , Chief Executive Officer of Histogenics ,
03/16/17
Summary ToggleHistogenics Corporation Announces Financial and Operating Results for the Fourth Quarter and Year Ended December 31, 2016 ‒ NeoCart ® Phase 3 Clinical Trial Enrollment on Track for Completion by End of Second Quarter of 2017 ‒ ‒ Strong Performance in all Areas of the Business in 2016 ‒ ‒ Financing Completed in the Third Quarter of 2016 Expected to Fund Company to Phase 3 Data ‒ ‒ Company to Host Conference Call and
03/09/17
Summary ToggleHistogenics Announces Publication of Biomechanical and Structural Data From Human Engineered Cartilage Testing – Data demonstrate Histogenics’ Tissue Engineered Cartilage Constructs Exhibit Mechanical Properties Approaching Native Human Cartilage as Early as Three Weeks in Culture and Prior to Implantation –  – First Study to Use Three Mechanical Tests to Examine and Understand the Performance of Repaired
03/02/17
Summary ToggleHistogenics Corporation to Announce 2016 Financial Results on March 16, 2017 WALTHAM, Mass. , March 02, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, announced it will release its financial and operational results for the quarter and year ended
02/23/17
Summary ToggleHistogenics Corporation to Present at Upcoming Investor Conferences WALTHAM, Mass. , Feb. 23, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation ( Histogenics ) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Company Management will be presenting at two upcoming
01/11/17
Summary ToggleHistogenics Announces Publication of MRI Data From NeoCart® Phase 1 and Phase 2 Clinical Trials in the American Journal of Sports Medicine – Data demonstrate significant improvement in cartilage quality over first 24 months after treatment, with stabilization and maturation thereafter out to 60 months –  – Improvements in cartilage quality were accompanied by consistent and statistically significant improvements in patient reported
11/10/16
Summary ToggleHistogenics Corporation Announces Third Quarter 2016 Financial and Operating Results - NeoCart ® Phase 3 Clinical Trial More than 75% Enrolled - - Enrollment On-Track to Complete by End of Second Quarter of 2017 - - Third Quarter Financing Expected to Fund Company to Phase 3 Data - - Company to Host Conference Call and Webcast Today at 8:30 a.m. EST - WALTHAM, Mass. , Nov.
10/27/16
Summary ToggleHistogenics Corporation to Announce Third Quarter 2016 Financial Results on November 10, 2016 WALTHAM, Mass. , Oct. 27, 2016 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, announced it will release its financial and operational results for the quarter ended September
10/24/16
Summary ToggleHistogenics Corporation Provides NeoCart® Phase 3 Clinical Trial Enrollment Update - 75% of Patients Enrolled in NeoCart Phase 3 Clinical Trial - WALTHAM, Mass. , Oct. 24, 2016 (GLOBE NEWSWIRE) -- Histogenics Corporation ( Histogenics ) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, announced that as
10/13/16
Summary ToggleHistogenics Corporation to Ring the Nasdaq Stock Market Closing Bell WALTHAM, Mass. , Oct. 13, 2016 (GLOBE NEWSWIRE) -- Histogenics Corporation ( Histogenics ) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, will ring the Closing Bell at Nasdaq today in celebration of its recently closed
10/06/16
Summary ToggleHistogenics Corporation Announces Addition of Dr. Lawrence Bonassar of Cornell University to Its Scientific Advisory Board - Company Adds Additional Leader in Tissue Engineering and Biomechanics - - Additional NeoCart ® Biomechanical Data Presented in Conjunction with Cornell University - WALTHAM, Mass. , Oct. 06, 2016 (GLOBE NEWSWIRE) -- Histogenics Corporation ( Histogenics ) (Nasdaq:HSGX), a regenerative medicine
09/29/16
Summary ToggleHistogenics Corporation Closes $30.0 Million Private Placement WALTHAM, Mass. , Sept. 29, 2016 (GLOBE NEWSWIRE) -- Histogenics Corporation ( Histogenics ) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced the closing of its previously disclosed $30.0 million private
09/26/16
Summary ToggleHistogenics Corporation to Present at the 2016 Cell & Gene Meeting on the Mesa WALTHAM, Mass. , Sept. 26, 2016 (GLOBE NEWSWIRE) -- Histogenics Corporation ( Histogenics ) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Adam Gridley , President and Chief Executive Officer of
09/16/16
Summary ToggleHistogenics Corporation Announces $30.0 Million Private Placement WALTHAM, Mass. , Sept. 16, 2016 (GLOBE NEWSWIRE) -- Histogenics Corporation ( Histogenics ) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that it has entered into a definitive securities purchase
08/31/16
Summary ToggleHistogenics Corporation to Present at the 18th Annual Rodman & Renshaw Global Investment Conference WALTHAM, Mass. , Aug. 31, 2016 (GLOBE NEWSWIRE) -- Histogenics Corporation ( Histogenics ) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Adam Gridley , President and Chief Executive Officer of
08/11/16
Summary ToggleHistogenics Corporation Announces Second Quarter 2016 Financial and Operating Results - NeoCart® Phase 3 Clinical Trial Remains on Track for Enrollment  Completion by End of Second Quarter of 2017 -  - Increasing Year-End 2016 Enrollment Guidance to 190 to 200 patients -  - Company to Host Conference Call and Webcast Today at 8:30 a.m. EDT - WALTHAM, Mass. , Aug.
07/28/16
Summary ToggleHistogenics Corporation to Announce Second Quarter 2016 Financial Results on August 11, 2016 WALTHAM, Mass. , July 28, 2016 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, announced it will release its financial and operational results for the quarter ended June 30,
07/27/16
Summary ToggleHistogenics Corporation to Present at the Canaccord Genuity Growth Conference WALTHAM, Mass. , July 27, 2016 (GLOBE NEWSWIRE) -- Histogenics Corporation ( Histogenics ) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Adam Gridley , President and Chief Executive Officer of
05/12/16
Summary ToggleHistogenics Corporation Announces First Quarter 2016 Financial and Operating Results - NeoCart® Phase 3 Clinical Trial Remains on Track for Enrollment  Completion by End of Second Quarter of 2017 - - Company to Host Conference Call and Webcast Today at 8:30 a.m. EDT - WALTHAM, Mass. , May 12, 2016 (GLOBE NEWSWIRE) -- Histogenics Corporation ( Histogenics ) (Nasdaq:HSGX), a
05/10/16
Summary ToggleHistogenics Corporation Acquires NeoCart® Development and Commercialization Rights for Japanese Market Developing Plans to Re-Engage with Japanese Regulatory Authorities and Seek Development and Commercialization Partners in Japan WALTHAM, Mass. , May 10, 2016 (GLOBE NEWSWIRE) -- Histogenics Corporation ( Histogenics ) (Nasdaq:HSGX), a regenerative medicine company focused on developing and
04/28/16
Summary ToggleHistogenics Corporation to Announce First Quarter 2016 Financial Results on May 12, 2016 WALTHAM, Mass. , April 28, 2016 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, announced it will release its financial and operational results for the quarter ended March 31,
03/31/16
Summary ToggleHistogenics Corporation To Present At Needham & Company’s 15th Annual Healthcare Conference WALTHAM, Mass. , March 31, 2016 (GLOBE NEWSWIRE) -- Histogenics Corporation ( Histogenics ) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Jonathan Lieber , Chief Financial Officer of Histogenics ,
03/14/16
Summary ToggleHistogenics Corporation to Present at 4th Annual Cell & Gene Therapy Investor Day WALTHAM, Mass. , March 14, 2016 (GLOBE NEWSWIRE) -- Histogenics Corporation ( Histogenics ) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Jonathan Lieber , Chief Financial Officer of Histogenics ,
03/10/16
Summary ToggleHistogenics Corporation Announces Financial and Operating Results for the Fourth Quarter and Year Ended December 31, 2015 - NeoCart® Phase 3 Clinical Trial More Than 50% Enrolled and on Track for Full Enrollment  by End of Second Quarter of 2017 - - Company to Host Conference Call and Webcast Today at 8:30 a.m. EST - WALTHAM, Mass. , March 10, 2016 (GLOBE NEWSWIRE) -- Histogenics Corporation ( Histogenics )
03/03/16
Summary ToggleHistogenics Corporation Announces Presentation of Data at Orthopaedic Research Society (ORS) Annual Meeting Histogenics’ Tissue Engineered Cartilage Exhibits Mechanical Properties Similar to Human Cartilage WALTHAM, Mass. , March 03, 2016 (GLOBE NEWSWIRE) -- Histogenics Corporation ( Histogenics ) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the
03/01/16
Summary ToggleHistogenics Corporation to Announce 2015 Financial Results on March 10, 2016 WALTHAM, Mass. , March 01, 2016 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, announced it will release its financial and operational results for the quarter and year ended
02/25/16
Summary ToggleHistogenics Corporation to Present at Upcoming Investor Conferences WALTHAM, Mass. , Feb. 25, 2016 (GLOBE NEWSWIRE) -- Histogenics Corporation ( Histogenics ) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Company Management will be presenting at two upcoming
02/02/16
Summary ToggleHistogenics Corporation Provides NeoCart® Phase 3 Clinical Trial Enrollment Update - 50% of Patients Enrolled in NeoCart Phase 3 Clinical Trial - WALTHAM, Mass. , Feb. 02, 2016 (GLOBE NEWSWIRE) -- Histogenics Corporation ( Histogenics ) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, announced that as
01/26/16
Summary ToggleHistogenics Corporation to Present at 18th Annual BIO CEO & Investor Conference WALTHAM, Mass. , Jan. 26, 2016 (GLOBE NEWSWIRE) -- Histogenics Corporation ( Histogenics ) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Adam Gridley , President and Chief Executive Officer of
01/06/16
Summary ToggleHistogenics Corporation to Present at Biotech Showcase 2016 WALTHAM, Mass. , Jan. 06, 2016 (GLOBE NEWSWIRE) -- Histogenics Corporation ( Histogenics ) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Adam Gridley , President and Chief Executive Officer of
12/21/15
Summary ToggleHistogenics Corporation Announces Amendment to NeoCart® Phase 3 Clinical Trial Enrollment Criteria Company and FDA Agree on Changes to Study Protocol Allowing for Modification of Patient Inclusion/Exclusion Criteria WALTHAM, Mass. , Dec. 21, 2015 (GLOBE NEWSWIRE) -- Histogenics Corporation ( Histogenics ) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing
11/12/15
Summary ToggleHistogenics Corporation Announces Third Quarter 2015 Financial and Operating Results - Completion of Enrollment of NeoCart® Phase 3 Trial Now Expected in Second Quarter of 2017 - - Company to Host Conference Call and Webcast Today at 8:30 a.m. EST - WALTHAM, Mass. , Nov. 12, 2015 (GLOBE NEWSWIRE) -- Histogenics Corporation ( Histogenics ) (Nasdaq:HSGX), a regenerative medicine
10/29/15
Summary ToggleHistogenics Corporation to Announce Third Quarter 2015 Financial Results on November 12, 2015 WALTHAM, Mass. , Oct. 29, 2015 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, announced it will release its financial and operational results for the third quarter ended
10/01/15
Summary ToggleHistogenics Corporation to Participate in Upcoming Scientific and Investor Conferences WALTHAM, Mass. , Oct. 1, 2015 (GLOBE NEWSWIRE) -- Histogenics Corporation ( Histogenics ) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Company Management will be participating in four upcoming
09/16/15
Summary ToggleHistogenics Corporation and Collagen Solutions plc Establish Supply Agreement WALTHAM, Mass. , Sept. 16, 2015 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space and Collagen Solutions plc (AIM:COS), the developer and manufacturer of medical grade collagen
08/12/15
Summary ToggleHistogenics Corporation Announces Second Quarter 2015 Financial and Operating Results - Continued Progress on NeoCart® Phase 3 Trial and 2015 Business Objectives - - Company to Host Conference Call and Webcast Today at 8:30 a.m. EDT - WALTHAM, Mass. , Aug. 12, 2015 (GLOBE NEWSWIRE) -- Histogenics Corporation ( Histogenics ) (Nasdaq:HSGX), a regenerative medicine company focused on
08/04/15
Summary ToggleHistogenics Corporation to Present at the Canaccord Genuity Growth Conference WALTHAM, Mass. , Aug. 4, 2015 (GLOBE NEWSWIRE) -- Histogenics Corporation ( Histogenics ) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Adam Gridley , President and Chief Executive Officer of
07/30/15
Summary ToggleHistogenics Corporation Announces Appointment of Stephen Kennedy to Chief Technology Officer Experienced Scientific and Technical Operations Executive Promoted to Lead Product Development and Manufacturing Operations WALTHAM, Mass. , July 30, 2015 (GLOBE NEWSWIRE) -- Histogenics Corporation ( Histogenics ) (Nasdaq:HSGX), a regenerative medicine company focused on developing and
07/27/15
Summary ToggleHistogenics Corporation to Announce Second Quarter 2015 Financial Results on August 12, 2015 WALTHAM, Mass. , July 27, 2015 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, announced it will release its financial and operational results for the second quarter ended
07/15/15
Summary ToggleHistogenics Corporation Announces Dr. Gloria Matthews as Chief Medical Officer Globally Recognized Thought Leader in Cell Therapy, Cartilage Repair and Orthopedics Joins Executive Team WALTHAM, Mass. , July 15, 2015 (GLOBE NEWSWIRE) -- Histogenics Corporation ( Histogenics ) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in
06/22/15
Summary ToggleHistogenics Corporation Announces Appointment of New Chief Financial Officer Experienced Financial and Investment Banking Executive Jonathan Lieber to Join Executive Team WALTHAM, Mass. , June 22, 2015 (GLOBE NEWSWIRE) -- Histogenics Corporation ( Histogenics ) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the
05/14/15
Summary ToggleHistogenics Corporation Announces First Quarter 2015 Financial Results WALTHAM, Mass. , May 14, 2015 (GLOBE NEWSWIRE) -- Histogenics Corporation ( Histogenics ) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, announced its financial and operational results for the first quarter ended March
05/11/15
Summary ToggleHistogenics Corporation Announces World Class Scientific Advisory Board to Support Commercialization and Pipeline Development WALTHAM, Mass. , May 11, 2015 (GLOBE NEWSWIRE) -- Histogenics Corporation ( Histogenics ) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, announced the creation of its new Scientific Advisory Board (SAB) comprised of
05/04/15
Summary ToggleHistogenics Corporation to Announce First Quarter 2015 Financial Results on May 14, 2015 WALTHAM, Mass. , May 4, 2015 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, announced it will release its financial and operational results for the first quarter ended March
04/02/15
Summary ToggleHistogenics Corporation to Present at the 14th Annual Needham Healthcare Conference WALTHAM, Mass. , April 2, 2015 (GLOBE NEWSWIRE) -- Histogenics Corporation ( Histogenics ) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Adam Gridley , President and Chief Executive Officer of
03/18/15
Summary ToggleHistogenics Corporation to Present at the Alliance for Regenerative Medicine (ARM) 3rd Annual Regen Med Investor Day WALTHAM, Mass. , March 18, 2015 (GLOBE NEWSWIRE) -- Histogenics Corporation ( Histogenics ) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Elissa Cote , Vice President of Marketing and External
03/17/15
Summary ToggleHistogenics Corporation to Present at the 2015 Canaccord Genuity Musculoskeletal Conference Histogenics Will Also Attend the American Association of Orthopaedic Surgeons (AAOS) WALTHAM, Mass. , March 17, 2015 (GLOBE NEWSWIRE) -- Histogenics Corporation ( Histogenics ) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal
02/26/15
Summary ToggleHistogenics Corporation Announces Fourth Quarter and Full Year 2014 Financial Results WALTHAM, Mass. , Feb. 26, 2015 (GLOBE NEWSWIRE) -- Histogenics Corporation ( Histogenics ) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, announced its financial and operational results for the fourth quarter and full
02/23/15
Summary ToggleHistogenics Corporation to Present at Cowen and Company 35th Annual Health Care Conference WALTHAM, Mass. , Feb. 23, 2015 (GLOBE NEWSWIRE) -- Histogenics Corporation ( Histogenics ) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Adam Gridley , President and Chief Executive Officer of
02/12/15
Summary ToggleHistogenics Corporation to Announce Fourth Quarter and Full Year 2014 Financial Results on February 26, 2015 WALTHAM, Mass. , Feb. 12, 2015 (GLOBE NEWSWIRE) -- Histogenics Corporation ( Histogenics ) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, announced it will release its financial and operational results for the fourth
02/02/15
Summary ToggleHistogenics Corporation Announces the Appointment of David Gill to Its Board of Directors and Chairman of Audit Committee Financial Expert to Serve as Chairman of Histogenics Audit Committee WALTHAM, Mass. , Feb. 2, 2015 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced the
12/02/14
Summary ToggleHistogenics Corporation Announces Pricing of Initial Public Offering WALTHAM, Mass. , Dec. 2, 2014 (GLOBE NEWSWIRE) -- Histogenics Corporation ( Histogenics ), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced the pricing of its underwritten initial public offering of 5,909,091 shares of
10/03/14
Summary ToggleHistogenics and Intrexon Announce Formation of Exclusive Channel Collaboration for Cartilage Repair Therapies Companies to Develop Universal Donor Chondrocyte Cell Treatments WALTHAM, Mass. and GERMANTOWN, Md., Oct. 3, 2014 /PRNewswire/ — Histogenics Corporation , a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, and Intrexon Corporation (NYSE:
07/02/14
Summary ToggleHistogenics Announces Appointment of Kathleen Large, R.N., M.S., to Vice President of Clinical Operations Waltham, MA., July 2, 2014 —Histogenics Corporation, a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced the appointment of Kathleen Large, R.N., M.S., to Vice President of Clinical Operations. Ms.
05/12/14
Summary ToggleHistogenics Announces Appointment of Adam Gridley to President and Chief Executive Officer Pharmaceutical Executive Brings Extensive Product Development & Operational Expertise to Late-Stage Regenerative Medicine Company Waltham, MA., May 12, 2014 —Histogenics Corporation, a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space,
11/14/13
Summary ToggleHistogenics announces appointment of John H. Johnson to its board of directors November 14, 2013 Waltham, Mass., November 14, 2013 —Histogenics Corporation, a late stage company focused on regenerative medicine technologies, today announced that John H. Johnson has been appointed to the company’s board of directors. Mr. Johnson is currently the chairman, president and chief
10/28/13
Summary ToggleHistogenics Announces Nancy Lynch, M.D., as CMO Orthopedic Surgeon and Venture Capitalist Brings Extensive Experience In Orthopedic Innovation Waltham, Mass. – October 28, 2013 – BUSINESS WIRE –Histogenics Corp., a biologics company leveraging the latest advances in bioengineering, proprietary materials science and molecular and cellular biology
08/20/13
Summary ToggleStephen Kennedy and Vladimir Scerbin Bring Specialized Expertise in Manufacturing, Operations, Supply Chain and Clinical Affairs August 20, 2013 Waltham, Mass., August 20, 2013 —Histogenics Corp., a late stage company developing novel tissue repair solutions initially targeting orthopedics, today announced the addition of two new members to its management team. Stephen Kennedy, previously with Genzyme, was added as Senior
06/10/13
Summary ToggleFormer MedImmune President Brings Extensive Development and Commercial Experience to Late-Stage Regenerative Medicine Company June 10, 2013 Waltham, Mass., June 10, 2013 —Histogenics Corp., a regenerative medicine company that combines cell therapy and tissue engineering technologies to develop highly innovative products primarily for orthopedic tissue repair, today announced the appointment of Peter Greenleaf to Chief
01/10/13
Summary ToggleHistogenics Proudly Supports the Major League Soccer Medical Symposium to Raise Awareness on Sports-Related Injuries January 10, 2013 Waltham, Mass. – January 10, 2013 – Histogenics Corp., a biologics company that combines cell therapy and tissue engineering technologies to develop highly innovative products primarily for sports-related and orthopedic tissue repair and regeneration, is proudly supporting this
11/12/12
Summary ToggleKevin Rakin Appointed to the Histogenics Board of Directors November 12, 2012 Waltham, Mass. – November 12, 2012 – Histogenics Corp., a biologics company that combines cell therapy and tissue engineering technologies to develop highly innovative products primarily for orthopaedic tissue repair and regeneration, today announced the appointment of Kevin L.
10/02/12
Summary ToggleHistogenics Honored as a 2012 “Fierce 15” Company by FierceMedicalDevices Histogenics’ NeoCart at the Forefront of Cartilage Regeneration Waltham, Mass. – October 2, 2012 – Histogenics, a regenerative medicine company combining cell therapy and tissue engineering technologies to develop highly innovative products for tissue repair and regeneration, announced today that
05/14/12
Summary ToggleHistogenics’ NeoCart for Patients with Knee Cartilage Damage Demonstrates Continued Efficacy for Periods of Up to Five Years Results presented at ICRS 2012 Annual Meeting by Dennis Crawford, MD WALTHAM, Mass. – May 14, 2012 – Regenerative medicine company Histogenics Corporation, announced today the presentation of intermediate data supporting the potential efficacy of the Company’s NeoCart Autologous Cartilage Tissue
07/27/11
Summary ToggleHistogenics Reports Positive Phase 2 Data for NeoCart Autologous Cartilage Tissue Implant for the Treatment of Knee Cartilage Injury Data at Two Years Post-Op Met Primary Endpoints WALTHAM, Mass. – July 27, 2011 – Histogenics Corporation, a privately held regenerative medicine company, today announced the presentation of positive Phase 2 data for the NeoCart Autologous Cartilage Tissue Implant (ACTI).